David Lebowitz
Stock Analyst at Citigroup
(3.96)
# 621
Out of 5,044 analysts
119
Total ratings
59.77%
Success rate
8.69%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $72.99 | +15.08% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $60.18 | +39.58% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $27.37 | +75.37% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $22.17 | -9.79% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $203.23 | +42.70% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $93.08 | +10.66% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $35.93 | +5.76% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $16.20 | +35.80% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $63.56 | +5.41% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $39.99 | +40.04% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $14.79 | -32.39% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.80 | -16.67% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $67.08 | -32.92% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $71.65 | -5.09% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $435.78 | -12.34% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $52.67 | +82.27% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.30 | +90.48% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $478.58 | -65.73% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $19.64 | +98.57% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $13.11 | +60.18% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.42 | +6,208.41% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.63 | +758.90% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $72.99
Upside: +15.08%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $60.18
Upside: +39.58%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $27.37
Upside: +75.37%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $22.17
Upside: -9.79%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $203.23
Upside: +42.70%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $93.08
Upside: +10.66%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $35.93
Upside: +5.76%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $16.20
Upside: +35.80%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $63.56
Upside: +5.41%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $39.99
Upside: +40.04%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $14.79
Upside: -32.39%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.80
Upside: -16.67%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $67.08
Upside: -32.92%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $71.65
Upside: -5.09%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $435.78
Upside: -12.34%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $52.67
Upside: +82.27%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.30
Upside: +90.48%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $478.58
Upside: -65.73%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $19.64
Upside: +98.57%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $13.11
Upside: +60.18%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.42
Upside: +6,208.41%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.63
Upside: +758.90%